Introduction to Jakavi 20mg Tablets:

JAKAVI 20MG contains Ruxolitinib which belongs to a group of medicines called kinase inhibitors. It is indicated to manage enlarged spleen or with symptoms related to myelofibrosis (a rare form of blood cancer). It is also used to control the haematocrit (the amount of red blood cells in the blood) in patients with polycythemia vera.

Ruxolitinib is a selective inhibitor of the Janus Kinases which blocks the action of certain enzymes and reduces the size of the spleen in patients with myelofibrosis and helps to reduce the risk of serious blood or vascular complications. This medicine also reduces the amount of red blood cells in the blood in patients with polycythemia vera.

Before taking JAKAVI 20MG, tell your physician if you have liver, kidney or heart problems, are pregnant or breastfeeding. This medicine is not suitable for use in children and adolescents below 18 years of age. The common side effects are headache, dizziness and infections.

Uses of Jakavi 20mg Tablets:

Myelofibrosis

Polycythemia vera

Acute-graft-versus host disease

Chronic-graft-versus host disease

How to use Jakavi 20mg Tablets:

Always take JAKAVI 20MG as instructed by your doctor. Swallow whole and do not crush or chew. It can be taken with or without food.